Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Estradiol Cypionate

FDA-approved product (injectable, injection), marketed as Depo-Estradiol, Estradiol Cypionate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Estradiol Cypionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrophic Vaginitis
  • Atrophy
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Dyspareunia
  • Hypogonadism
  • Menopause
  • Osteoporosis
  • Postmenopausal atrophic vaginitis
  • Postmenopausal osteoporosis
  • Premature ovarian insufficiency
  • Primary ovarian insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural and semisynthetic estrogens, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Estradiol Cypionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Estradiol Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

    NCT07792408 · start 2026-08-28

    Registered record
    Registry ID
    NCT07792408
    Conditions
    Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Interventions
    VX-407; LNG/EE; NGM/EE; NET/EE; DRSP/EE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08-28
    Completion
    2027-03-20
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutosomal Dominant Polycystic Kidney Disease (ADPKD)
    InterventionVX-407; LNG/EE; NGM/EE; NET/EE +1 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    NCT07287917 · start 2026-01-26

    Registered record
    Registry ID
    NCT07287917
    Conditions
    Melanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer
    Interventions
    AMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-01-26
    Completion
    2028-12-29
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer
    InterventionAMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin

    NCT07269327 · start 2025-11-24

    Registered record
    Registry ID
    NCT07269327
    Conditions
    Fertility
    Interventions
    Desogestrel and ethinylestradiol fixed dose combination; Follitropin alfa/lutropin alfa
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-11-24
    Completion
    2026-03-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFertility
    InterventionDesogestrel and ethinylestradiol fixed dose combination; Follitropin alfa/lutropin alfa
    PhasePhase 1
    Registry statusCompleted

  • IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women

    NCT07171970 · start 2025-09-22

    Registered record
    Registry ID
    NCT07171970
    Conditions
    Polycystic Ovary Syndrome (PCOS); In Vitro Maturation of Oocytes; Fresh Embryo Transfer
    Interventions
    IVM-Fresh (No gonadotropin + Fresh embryo transfer); IVF-FET (GnRH-Antagonist - Agonist Trigger - Frozen embryo transfer)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-09-22
    Completion
    2028-01-15
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome (PCOS); In Vitro Maturation of Oocytes; Fresh Embryo Transfer
    InterventionIVM-Fresh (No gonadotropin + Fresh embryo transfer); IVF-FET (GnRH-Antagonist - Agonist Trigger - Frozen embryo transfer)
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency

    NCT07020429 · start 2025-09-01

    Registered record
    Registry ID
    NCT07020429
    Conditions
    Premature Ovarian Insufficiency
    Interventions
    Huanjingjian decoction; Hormone replacement therapy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2030-07-30
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Ovarian Insufficiency
    InterventionHuanjingjian decoction; Hormone replacement therapy; Placebo
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users

    NCT07083635 · start 2025-07-29

    Registered record
    Registry ID
    NCT07083635
    Conditions
    Menstruation Disturbances; Metrorrhagia; Uterine Hemorrhage; Contraception Behavior
    Interventions
    Transdermal Ethinyl Estradiol/Norelgestromin Patch; Placebo Patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2026-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenstruation Disturbances; Metrorrhagia; Uterine Hemorrhage; Contraception Behavior
    InterventionTransdermal Ethinyl Estradiol/Norelgestromin Patch; Placebo Patch
    PhasePhase 2
    Registry statusRecruiting

  • Postpartum Vaginal Estrogen for Breastfeeding Patients

    NCT05457972 · start 2025-02-22

    Registered record
    Registry ID
    NCT05457972
    Conditions
    Breastfeeding; Postpartum Sexual Dysfunction; Vaginal Atrophy
    Interventions
    Estradiol; Vaginal Moisturizer
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-02-22
    Completion
    2026-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreastfeeding; Postpartum Sexual Dysfunction; Vaginal Atrophy
    InterventionEstradiol; Vaginal Moisturizer
    PhasePhase 4
    Registry statusRecruiting

  • A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

    NCT06799884 · start 2025-01-18

    Registered record
    Registry ID
    NCT06799884
    Conditions
    Drug Drug Interaction
    Interventions
    Ethinyl Estradiol / Levonorgestrel Oral Tablet; Aprocitentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-01-18
    Completion
    2025-02-21
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction
    InterventionEthinyl Estradiol / Levonorgestrel Oral Tablet; Aprocitentan
    PhasePhase 1
    Registry statusCompleted

  • A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

    NCT06680921 · start 2024-11-14

    Registered record
    Registry ID
    NCT06680921
    Conditions
    Locally Advanced or Metastatic Breast Cancer
    Interventions
    SIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-11-14
    Completion
    2028-08-31
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced or Metastatic Breast Cancer
    InterventionSIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    PhasePhase 3
    Registry statusActive not recruiting

  • Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

    NCT05063786 · start 2021-09-14

    Registered record
    Registry ID
    NCT05063786
    Conditions
    Advanced Breast Cancer
    Interventions
    Trastuzumab; Alpelisib; Fulvestrant; Vinorelbine; Capecitabine; Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-14
    Completion
    2026-06
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionTrastuzumab; Alpelisib; Fulvestrant; Vinorelbine +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

    NCT04753177 · start 2021-01-28

    Registered record
    Registry ID
    NCT04753177
    Conditions
    The Neoadjuvant Therapy
    Interventions
    Ribocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-01-28
    Completion
    2024-01-28
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Neoadjuvant Therapy
    InterventionRibocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)

    NCT04002635 · start 2020-12-01

    Registered record
    Registry ID
    NCT04002635
    Conditions
    Infertility, Female; Polycystic Ovary Syndrome; IVF; Ovulation Disorder
    Interventions
    Letrozole; estradiol valerate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2020-12-01
    Completion
    2022-04-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Polycystic Ovary Syndrome; IVF; Ovulation Disorder
    InterventionLetrozole; estradiol valerate
    PhasePhase 4
    Registry statusWithdrawn

  • A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

    NCT04282031 · start 2020-06-15

    Registered record
    Registry ID
    NCT04282031
    Conditions
    Advanced Solid Tumor; HR+/HER2- Breast Cancer
    Interventions
    BPI-1178; Fulvestrant; Letrozole; BPI-1178
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-06-15
    Completion
    2025-06-30
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; HR+/HER2- Breast Cancer
    InterventionBPI-1178; Fulvestrant; Letrozole; BPI-1178
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

    NCT04247126 · start 2020-01-23

    Registered record
    Registry ID
    NCT04247126
    Conditions
    Advanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer
    Interventions
    SY-5609; Fulvestrant; Gemcitabine; Nab-paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-23
    Completion
    2023-03-30
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer
    InterventionSY-5609; Fulvestrant; Gemcitabine; Nab-paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women

    NCT03815929 · start 2019-03-15

    Registered record
    Registry ID
    NCT03815929
    Conditions
    Cardiovascular Risk Reduction
    Interventions
    Estradiol 100 Micrograms Patch; Estradiol Patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-03-15
    Completion
    2023-08-28
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Risk Reduction
    InterventionEstradiol 100 Micrograms Patch; Estradiol Patch
    PhasePhase 2
    Registry statusCompleted